Novartis AG Form 6-K Summary: Full Year 2011
Business Context and Reporting Period
This Form 6-K, dated January 25, 2012, reports the financial results for Novartis AG for the fourth quarter and full year ended December 31, 2011. The reporting period reflects the full integration of Alcon as the second-largest division within the Novartis Group. The company operates across Pharmaceuticals, Alcon (Eye Care), Sandoz (Generics), Vaccines and Diagnostics, and Consumer Health.
Key Financial Metrics
| Metric | Q4 2011 (USD) | FY 2011 (USD) | FY 2010 (USD) |
|---|---|---|---|
| Net Sales | $14.8 billion | $58.6 billion | $50.6 billion |
| Operating Income | $1.3 billion | $11.0 billion | $11.5 billion |
| Net Income | $1.2 billion | $9.2 billion | $10.0 billion |
| EPS (Diluted) | $0.48 | $3.78 | $4.26 |
| Free Cash Flow | $3.9 billion | $12.5 billion | $12.3 billion |
| Net Debt | Ended FY 2011 at $15.2 billion |
Core Performance (Constant Currency): Full year core operating income grew 16% to $15.9 billion, with a core margin of 27.2%. Core EPS increased 11% to $5.57.
Material Changes vs. Prior Period
- Revenue Growth: Full year net sales rose 16% (12% in constant currency), driven by recently launched products which contributed 25% of total sales. Pharmaceuticals sales grew 7% (4% cc), while Alcon sales grew 10% (7% cc) on a pro forma basis.
- Profitability Decline (GAAP): Reported operating income fell 5% and net income fell 7% year-over-year. This was primarily due to $1.9 billion in net exceptional charges for the full year, including $903 million related to the Tekturna/Rasilez portfolio and $492 million in restructuring costs.
- Core Profitability Growth: Excluding exceptional items and amortization, core operating income increased 14% (16% cc), demonstrating underlying operational strength despite currency headwinds.
- Divisional Performance: Vaccines and Diagnostics sales dropped 32% due to the absence of $1.3 billion in A(H1N1) pandemic vaccine sales recorded in 2010. Sandoz sales grew 10% (7% cc) despite price erosion.
Outlook, Risks, and Management Commentary
- 2012 Guidance: Novartis expects 2012 sales to be in line with 2011 levels. Core operating income margin in constant currencies is expected to be slightly below 2011 levels.
- Key Risks & Headwinds:
- Patent Expirations: Significant revenue loss anticipated from Diovan (loss of exclusivity in EU) and Tekturna/Rasilez (sales expected to be less than half of 2011).
- Clinical Trial Halts: The ALTITUDE study for Tekturna/Rasilez was halted due to higher adverse events in patients with diabetes taking the drug in combination with ACE inhibitors or ARBs. Promotion for this combination has ceased.
- Regulatory Reviews: Ongoing FDA and EMA reviews of Gilenya following a patient death within 24 hours of the first dose. New interim recommendations for ECG monitoring have been issued in the EU.
- Manufacturing Issues: Temporary suspension of production at a US Consumer Health site (Lincoln, Nebraska) led to product recalls and a $115 million charge.
- Dividend: The Board proposed a dividend of CHF 2.25 per share for 2011, marking the 15th consecutive annual increase.
Investor Verification Checklist
- Verify the impact of the halted ALTITUDE study on future Tekturna/Rasilez revenue projections and potential litigation risks.
- Monitor the outcome of the FDA and EMA reviews regarding Gilenya safety and any resulting label changes or sales restrictions.
- Assess the timeline for the restart of the Lincoln, Nebraska manufacturing facility and its impact on Consumer Health sales recovery.
- Review the progress of recently launched products (Gilenya, Tasigna, Lucentis) to confirm they are offsetting patent cliff losses from Diovan and Femara.
- Confirm the execution of cost-saving measures and productivity initiatives to maintain core margins in 2012 despite expected revenue flatness.